Holmium laser technologies versus photoselective greenlight vaporization for patients with benign prostatichyperplasia: a meta-analysis
Holmium laser technologies versus photoselective greenlight vaporization for patients with benign prostatichyperplasia: a meta-analysis
复制标题
钬激光技术与光选择性绿光汽化治疗良性前列腺增生患者的对比：一项荟萃分析
DOI：
10.1007/s10103-020-02953-z
复制
发表时间：
2020-01
影响因子：
2.1
通讯作者：
De-Yi Luo
中科院分区：
文献类型：
--
作者：
Liao Peng;Xiao-Nan Zheng;Jia-Pei Wu;Xiao Zeng;Qing He;Guo Chen;Tian-Hai Lin;Hong Shen;De-Yi Luo
本研究旨在比较钬激光技术（HoL-Ts）和光选择性绿光汽化术（PVP）治疗良性前列腺增生（BPH）的有效性和安全性，并根据PubMed、EMBASE、ClinicalTrial.gov和科克伦对照试验中心截至2019年8月的系统性综述和荟萃分析指南的首选报告项目进行荟萃分析。纳入并分析功能结局、围手术期参数和并发症。使用Review Manager 5.3（科克伦协作网，牛津，英国）进行所有分析。本综述共纳入6篇文章，包括2014例患者。与PVP相比，HoL-Ts在1个月、3个月和6个月的Qmax中具有更好的性能（P= 0.02，但I2 = 81%），排尿后残余尿量（PVR）较少（MD = −33.85，95%CI −52.13至− 15.57，P = 0.0003）和使用的总能量较少（MD = −31.66，95%CI −58.99至− 4.33，P = 0.02）。HoL-Ts组的中转开腹率相对较低（OR = 0.08，95%CI 0.01 ~ 0.60，P = 0.01），且术中出血量少、眼球摘除量大。钬激光前列腺剜除术（HoLEP）与PVP相比的亚组分析表明，HoLEP在1个月、3个月、6个月和1年Qmax时的结果更好，PVR更少，能量消耗更少，转换率更低。与PVP相比，HoL-Ts的1、3和6个月Qmax更高，PVR更低，总能量消耗更少，转换率风险相对较低。在亚组分析中，HoLEP显示出与所有HoL-T一致的更好结果。然而，需要设计良好的随机对照试验（包括整体功能指标）来证实我们的研究结果。
This study aims to compare the efficacy and safety of holmium laser technologies (HoL-Ts) and photoselective greenlight vaporization (PVP) for the treatment of benign prostatic hyperplasia (BPH), and to perform a meta-analysis according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses guidelines on PubMed, EMBASE, ClinicalTrial.gov, and the Cochrane Central Register of Controlled Trials up to August 2019. Functional outcomes, perioperative parameters, and complications were included and analyzed. Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) was used to perform all analyses. A total of six articles composed of 2014 patients were included in this review. In comparison with PVP, HoL-Ts had a better performance in 1-, 3-, and 6-month Qmax (P= 0.02, butI2= 81%), with less postvoid residual urine volume (PVR) (MD = −33.85, 95% CI −52.13 to −15.57,P= 0.0003) and less total energy used (MD = −31.66, 95% CI −58.99 to −4.33,P= 0.02). Moreover, HoL-Ts had a relatively lower risk of conversion rate (OR = 0.08, 95% CI 0.01 to 0.60,P= 0.01) associated with enough enucleation and less intraoperative bleeding. Subgroup analysis of holmium laser enucleation of prostate (HoLEP) versus PVP suggested that HoLEP presented better results in 1-, 3-, 6-month and 1-year Qmax with less PVR, less energy consumption, and lower conversion rate. Compared with PVP, HoL-Ts had higher 1-, 3-, and 6-month Qmax, less PVR, and less total energy consumption with a relatively lower risk of conversion rate. In subgroup analyses, HoLEP had shown better results in accordance with all HoL-Ts. Nevertheless, well-designed RCTs including overall functional indicators are required to confirm our findings.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
2.7
作者：
Yamada, Yasushi;Furusawa, Jun;Kuromatsu, Isao
通讯作者：
Kuromatsu, Isao
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
--
发表时间：
2010
期刊：
--
影响因子：
--
作者：
S. Imagama;Y. Matsuyama;Y. Yukawa;N. Kawakami;M. Kamiya;T. Kanemura;N. Ishiguro;Ñ. S. Imagama
通讯作者：
S. Imagama;Y. Matsuyama;Y. Yukawa;N. Kawakami;M. Kamiya;T. Kanemura;N. Ishiguro;Ñ. S. Imagama
影响因子：
4.6
作者：
Sun, Inyoung;Yoo, Sangjun;Cho, Min Chul
通讯作者：
Cho, Min Chul